Trial Profile

SOLAIRIA-2: A phase 3 study of GB-0895 in patients with severe asthma whose disease remains inadequately controlled on current therapies

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Dec 2025 New trial record
01 Dec 2025 According to a Generate Biomedicines media release, SOLAIRIA-1 and SOLAIRIA-2 will enroll across more than 40 countries in North America, Europe, Latin America, and Asia Pacific.
01 Dec 2025 According to a Generate Biomedicines media release, the company plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in approximately 1,600 adults and adolescents with severe asthma whose disease remains inadequately managed on current therapies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com